21311578

Source:http://linkedlifedata.com/resource/pubmed/id/21311578

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0017243, umls-concept:C0034656, umls-concept:C0036043, umls-concept:C0043210, umls-concept:C0205390, umls-concept:C0439228, umls-concept:C0585361, umls-concept:C1433525, umls-concept:C1521801, umls-concept:C1696465, umls-concept:C2587213
pubmed:issue	1
pubmed:dateCreated	2011-2-11
pubmed:abstractText	To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18-24 years in the USA and Kenya.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/HHSN266200400074C, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR024131
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-10448335, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-11040059, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-11170957, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-11176265, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-11399958, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-12103432, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-12443969, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-14616702, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-15325893, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-15388443, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-15577653, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-16219368, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-16284466, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-16641437, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-16860051, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-1706728, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-17334265, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-17417133, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-17586138, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-18226677, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-19823111, http://linkedlifedata.com/resource/pubmed/commentcorrection/21311578-20588163
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101285081
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents, http://linkedlifedata.com/resource/pubmed/chemical/Gels, http://linkedlifedata.com/resource/pubmed/chemical/Polylysine, http://linkedlifedata.com/resource/pubmed/chemical/SPL7013
pubmed:status	MEDLINE
pubmed:issn	1932-6203
pubmed:author	pubmed-author:BrownJoelleJ, pubmed-author:BukusiElizabeth AEA, pubmed-author:CohenCraig RCR, pubmed-author:MoscickiAnna-BarbaraAB, pubmed-author:PaullJeremy R AJR, pubmed-author:PriceClare FCF, pubmed-author:ShiboskiStephenS
pubmed:issnType	Electronic
pubmed:volume	6
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	e16258
pubmed:meshHeading	pubmed-meshheading:21311578-Administration, Intravaginal, pubmed-meshheading:21311578-Adolescent, pubmed-meshheading:21311578-Adult, pubmed-meshheading:21311578-Anti-Infective Agents, pubmed-meshheading:21311578-Colposcopy, pubmed-meshheading:21311578-Drug Toxicity, pubmed-meshheading:21311578-Erythema, pubmed-meshheading:21311578-Female, pubmed-meshheading:21311578-Female Urogenital Diseases, pubmed-meshheading:21311578-Gels, pubmed-meshheading:21311578-Humans, pubmed-meshheading:21311578-Kenya, pubmed-meshheading:21311578-Lactobacillus, pubmed-meshheading:21311578-Polylysine, pubmed-meshheading:21311578-Sexual Abstinence, pubmed-meshheading:21311578-United States, pubmed-meshheading:21311578-Young Adult
pubmed:year	2011
pubmed:articleTitle	A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.
pubmed:affiliation	Department of Obstetrics, Gynecology and Reproductive Science, University of California San Francisco, San Francisco, California, United States of America. ccohen@globalhealth.ucsf.edu
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Research Support, N.I.H., Extramural